Baxter's vaccines, soon to be Pfizer's, help it exceed Q3 guidance; Pfenex and PATH partner up;

> Baxter's ($BAX) marketed vaccines--on their way to Pfizer ($PFE) thanks to a July deal--chipped in $21 million, or $0.04 per diluted share, in net income for Q3. Release

> Pfenex ($PFNX) and PATH have partnered up to enhance vaccine production; the two are working on an initial pilot project for two vaccine components. More

> Vaxart's tablet vaccine for H1N1 influenza generated protective immunity equivalent to an injectable in a Phase I clinical trial. Release

> The International Medica Foundation has licensed to BravoVax a rotavirus vaccine for newborns. More

> Unexpected delays from multiple manufacturers are causing postponements of flu shipments to some healthcare providers, according to distributor FFF. Release

> France's Imaxio has inked an option for a license agreement with the German Center for Cancer Research to evaluate the former's pro-immunogenic technology with a candidate vaccine targeting HPV. More

And Finally... The Vaccine & Gene Therapy Institute of Florida (VGTI Florida) has partnered with Sweden's Karolinska Institutet to fight diseases associated with aging. More (sub. req.)